表 3.
MLL-AF6阳性AML患者免疫表型、分子生物学特征及转归
Immunophenotypic, molecular biological characteristics and outcomes of AML patients with MLL-AF6 positive
| No. | Immunotype | Level of MLL-AF6/% | Level of EVI1/% | Induction regimen | CR | allo-HSCT | Outcome | OS/month |
| CR, complete response; allo-HSCT, allogeneic hematopoietic stem cell transplantation; OS, overall survival; Y, yes; N, no; IA, idarubicin+cytarabine; Dac+CAG, decitabine+cytarabine+aclacinomycin+granulocyte colony stimulating factor; DA, daunorubicin+cytarabine. | ||||||||
| 1 | CD34, CD13, CD33, HLA-DR, CD15, CD4 | 14.2 | - | IA | Y | Y | Dead | 9 |
| 2 | CD34, CD123, CD117, CD13, CD33, HLA-DR, CD64, CD11b, cMPO | 57.6 | - | IA | Y | Y | Dead | 14 |
| 3 | CD117, CD13, CD33, HLA-DR, CD64, CD56, cMPO | 59.3 | 151.6 | IA | N | Y | Dead | 7 |
| 4 | CD34, CD117, CD33, CD13, CD9, HLA-DR, CD38, CD15 | 68.0 | 289.4 | IA | Y | Y | Dead | 13 |
| 5 | CD117, CD33, CD38, CD15, HLA-DR, CD56, CD64, CD11, cCD4, CXCR4, CD11b | 70.1 | - | Dac+CAG | Y | N | Dead | 5 |
| 6 | CD34, CD123, CD117, CD13, CD33, HLA-DR, CD38, CD64 | 138.2 | 339.6 | IA | Y | N | Dead | 9 |
| 7 | CD117, CD13, CD33, CD38, HLA-DR, CD16, CD11b, CD15, CD4, CD64, CD36, CD56, cMPO | 25.0 | - | Dac+CAG | N | Y | Dead | 9 |
| 8 | CD34, CD13, CD33, HLA-DR, CD4, CD15 | 36.6 | 75.8 | IA | Y | N | Dead | 5 |
| 9 | CD34, CD123, CD117, CD13, CD33, HLA-DR, CD9, CD64, cMPO, CD36, CD11b | 96.8 | 34.1 | IA | Y | N | Dead | 16 |
| 10 | CD34, CD123, CD117, CD33, CD13, CD38, HLA-DR, CD11b, CD36, CD64, CD11c, CD14, CD15 | 214.5 | 154.4 | Dac+DA | N | N | Alive | 2 |
| 11 | CD34, CD33, HLA-DR, CD4, CD11b, CD38, CD56, CD64 | 29.1 | - | IA | Y | N | Alive | 11 |